Entero Healthcare Solutions: Business Overview & Financial Analysis
Entero Healthcare Solutions Limited is a leading tech-enabled healthcare products distribution platform in India. Founded in 2018 by Prabhat Agrawal and Prem Sethi, the company provides supply chain and distribution solutions to pharmacies, hospitals, and clinics across India. Operating through a centralized technology infrastructure, Entero Healthcare Solutions aggregates demand across retail chemists and healthcare institutions to supply pharmaceutical drugs, surgical items, and MedTech devices.
Operating Scale Metrics of Entero Healthcare (Q1 FY2027)
Entero Healthcare Solutions tracks retail chemist penetration, hospital coverage, SKU scale, and warehouse distribution points nationwide.
- Active Retail Chemist Accounts – 72,000+ retail pharmacies
- Active Hospital & Institutional Clients – 2,300+ healthcare institutions
- Active SKU Catalog Scale – 83,400+ healthcare product SKUs
- Manufacturing Partner Relationships – 3,000+ pharma & MedTech manufacturers
- Warehouse Distribution Hubs Base – 138 operational warehouses
- Geographic District Coverage – 475 districts across 19 Indian states
Operating 138 warehouses across 475 districts ensures product availability and fill rates for retail chemists. Partnering with 3,000+ manufacturers enables broad SKU distribution across pharmaceutical and MedTech lines.
Product & Segment Revenue Mix of Entero Healthcare (Q1 FY2027)
Entero Healthcare Solutions structures its commercial distribution operations across Core Pharmaceuticals, Surgical Consumables, and MedTech Devices.
- Pharmaceuticals Distribution Share – 82.5% of Total Revenue
- MedTech & Surgical Devices Share – 17.5% of Total Revenue
- Total Consolidated Revenue from Operations (Q1 FY2027) – Rs 1,940.50 crore (+38.2% YoY)
Core pharmaceutical distribution serves as the primary revenue driver across retail pharmacy channels. Expanding high-margin MedTech product distribution strengthens overall gross profit margins.
Revenue Growth Composition of Entero Healthcare (Q1 FY2027)
The company analyzes top-line revenue performance across organic growth and inorganic calendarization of historical acquisitions.
- Total Consolidated Revenue Growth Rate – +38.2% YoY growth
- Organic Growth Rate Contribution – +17.8% reported organic growth (+19.6% like-for-like basis)
- Inorganic Growth Rate Contribution – +20.4% from calendarization of prior year acquisitions
- Low-Margin Business Rationalization Drag – ~2.5% deliberate revenue exit from low-margin accounts
Organic revenue grew 19.6% on a like-for-like basis, driven by wallet share expansion across retail chemist accounts. Exiting select low-margin accounts expanded operating EBITDA margins.
Latest Quarterly Financial Performance of Entero Healthcare (Q1 FY2027)
Entero Healthcare Solutions recorded strong top-line revenue expansion and operational EBITDA margin expansion during the first quarter of FY2027.
- Consolidated Revenue from Operations – Rs 1,940.50 crore (+38.2% YoY vs Rs 1,403.80 crore in Q1 FY2026)
- Gross Profit Realised – Rs 221.40 crore (+58.6% YoY vs Rs 139.60 crore in Q1 FY2026)
- Gross Profit Margin Realisation – 11.41% (+147 bps YoY vs 9.94%)
- Consolidated Operating EBITDA – Rs 97.00 crore (+93.6% YoY vs Rs 50.10 crore in Q1 FY2026)
- Consolidated Operating EBITDA Margin – 5.00% (+143 bps YoY vs 3.57%)
- Consolidated Net Profit After Tax (PAT) – Rs 52.10 crore (+72.5% YoY vs Rs 30.20 crore in Q1 FY2026)
- Consolidated Net PAT Margin Realisation – 2.68% (+50 bps YoY)
First-quarter consolidated operating revenue expanded 38.2% year-on-year to Rs 1,940.50 crore, supported by volume off-take in core distribution channels. Consolidated Net Profit After Tax reached Rs 52.10 crore, while operating EBITDA margins hit a landmark 5.00%.
Consolidated Annual Financial Performance of Entero Healthcare (FY2026)
The enterprise achieved full-year turnover expansion and bottom-line earnings growth during full financial year FY2026.
- Full Year Consolidated Revenue from Operations – Rs 6,591.21 crore (+29.35% YoY vs Rs 5,095.60 crore in FY2025)
- Full Year Consolidated Operating EBITDA – Rs 268.40 crore (+45.2% YoY)
- Full Year Operating EBITDA Margin – 4.07%
- Full Year Consolidated Net Profit After Tax (PAT) – Rs 138.50 crore (+36.2% YoY)
- Return on Capital Employed (ROCE) Realisation – 21.10% (as of Q1 FY2027)
- Return on Equity (ROE) Realisation – 20.40% (as of Q1 FY2027)
Full-year operating turnover crossed Rs 6,590.00 crore in FY2026, as consolidated Net Profit After Tax expanded 36.2%. Delivering a return on capital employed of 21.10% reflects procurement economies across distribution warehouses.
Balance Sheet Structure & Working Capital Ratios of Entero Healthcare (Q1 FY2027)
Entero Healthcare Solutions operates a capital structure supported by equity net worth, IPO proceeds, and working capital lines.
- Net Operating Working Capital Days – 61 days (Improved vs 66 days in Q1 FY2026)
- Quarterly Annualized Finance Costs Outlay – Rs 18.10 crore (vs Rs 8.30 crore in Q1 FY2026)
- Non-Controlling Interest Share (Minority Interest) – Rs 13.90 crore in Q1 FY2027
- Current Ratio Status – 2.26x
Improving net operating working capital cycle down to 61 days supports operating cash flow conversion across warehouse distribution hubs. Managing a 2.26x current ratio maintains short-term liquidity across supplier payables.
MedTech Expansion & Business Target Roadmap of Entero Healthcare (FY2027–FY2028)
The company executes a growth strategy to scale its MedTech product distribution, expand warehouse automation, and execute call options on minority stakes.
- MedTech Annual Revenue Target Guidance – Projecting organic MedTech revenue to cross Rs 1,000.00 crore in FY2027
- Medium-Term Operating EBITDA Margin Target – Targeting sustainable EBITDA margins above 6.00%
- Target EBITDA to Operating Cash Flow Conversion – 50.0% annual cash conversion guidance
- Minority Stake Call Option Execution – Pre-agreed call options to acquire residual minority stakes over 2 to 5 years
- Funding Strategy – Funded through internal operational cash accruals and unutilized IPO proceeds
Scaling organic MedTech distribution past Rs 1,000.00 crore expands gross margins due to demand generation pricing power. Executing pre-agreed call options on minority stakes consolidates earnings ownership across subsidiary units.
Strategic Outlook & Management Commentary of Entero Healthcare (Q1 FY2027 Concall)
Management guidance outlines strategic priorities centered on organic growth acceleration, margin expansion, and working capital optimization.
- Management reiterates FY2027 consolidated revenue growth guidance of ~23.0% excluding new acquisitions.
- Consolidated operating EBITDA margin is guided to sustain at 5.0% for FY2027 and expand past 6.0% over the medium term.
- Medium-term consolidated top-line growth is targeted at ~20.0% annually even without fresh acquisitions.
- MedTech division is on track to cross Rs 1,000.00 crore in organic revenue during full financial year FY2027.
- Procurement economies and operating leverage will remain primary drivers for gross margin expansion.
- Operating cash flow conversion is guided at 50.0% of annual operating EBITDA.
- Capital allocation strategy will prioritize organic market share gains and working capital optimization over aggressive M&A.
Management anticipates strong pharmaceutical demand and MedTech penetration to support full-year turnover targets. Operational focus centers on sustaining 5.0%+ EBITDA margins, scaling MedTech revenue past Rs 1,000 crore, and maintaining working capital discipline.
Want to filter out stocks based on your own investment criteria? You can use the Stock Screener on Finology Ticker to evaluate stocks based on customised valuation and profitability parameters.
Sources & References
- Entero Healthcare Solutions Q1 FY2027 Financial Disclosures & Stock Exchange Outcomes
- Entero Healthcare Solutions Q1 FY2027 Investor Presentation & Concall Summary
- Stock Exchange Outcomes & BSE/NSE Regulatory Filings for Entero Healthcare Solutions
- Corporate Update & Financial Results Analysis for Entero Healthcare
- Ticker Finology Entero Healthcare Solutions Page
Disclaimer
The information presented above on Entero Healthcare Solutions has been compiled from the company's Annual Reports, Investor Presentations, Earnings Call (Concall) Transcripts, official regulatory filings and the financial data available on Finology Ticker. Certain figures, classifications or comparisons may vary due to differences in accounting policies, reporting methodologies or subsequent restatements by the company. This content is intended solely for informational purposes and should not be considered as investment advice. Investors are advised to refer to the latest company filings and the updated financial data, ratios and disclosures available on this Finology Ticker Entero Healthcare Solutions page before making any investment decision. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.